1
00:00:00,000 --> 00:00:05,542
SS-31, also called elamipretide, is a four-amino-acid peptide studied for its effects on

2
00:00:05,542 --> 00:00:09,167
mitochondria.

3
00:00:09,167 --> 00:00:15,583
Its story shows why a promising mechanism, an animal experiment, and a human treatment claim

4
00:00:15,583 --> 00:00:19,208
are different kinds of evidence.

5
00:00:19,208 --> 00:00:24,333
The central target is cardiolipin, a lipid in the inner mitochondrial membrane.

6
00:00:24,333 --> 00:00:29,458
Laboratory experiments found that SS-31 interacts with cardiolipin and can limit the

7
00:00:29,458 --> 00:00:34,583
damaging peroxidase activity of cytochrome c, a protein that normally helps transfer

8
00:00:34,583 --> 00:00:38,208
electrons.

9
00:00:38,208 --> 00:00:42,917
Related experiments in isolated mitochondria found improvements in electron transport and

10
00:00:42,917 --> 00:00:46,542
ATP production.

11
00:00:46,542 --> 00:00:52,500
These findings explain a biological rationale. They do not establish a general energy boost

12
00:00:52,500 --> 00:00:56,125
in people.

13
00:00:56,125 --> 00:01:02,542
In a rat model of interrupted blood flow to the kidneys, pretreatment with SS-31 preserved

14
00:01:02,542 --> 00:01:06,833
mitochondrial membrane folds and supported recovery after blood flow returned.

15
00:01:06,833 --> 00:01:13,250
That is evidence from a particular injury model, not proof of human rejuvenation or longer

16
00:01:13,250 --> 00:01:16,875
life.

17
00:01:16,875 --> 00:01:21,583
In MMPOWER-3, a randomized trial involving 218 participants with primary mitochondrial

18
00:01:21,583 --> 00:01:26,292
myopathy, elamipretide did not significantly improve six-minute walking distance or fatigue

19
00:01:26,292 --> 00:01:29,917
compared with placebo after 24 weeks.

20
00:01:29,917 --> 00:01:33,542
Exploratory findings should not replace that overall result.

21
00:01:33,542 --> 00:01:39,083
In Barth syndrome, a separate randomized crossover study of twelve participants also failed

22
00:01:39,083 --> 00:01:43,375
to show benefit on its primary walking and fatigue endpoints.

23
00:01:43,375 --> 00:01:47,667
Improvements were subsequently observed during an open-label extension, when participants

24
00:01:47,667 --> 00:01:52,792
knew they were receiving treatment and there was no concurrent placebo group.

25
00:01:52,792 --> 00:01:56,417
Those design differences matter.

26
00:01:56,417 --> 00:02:01,542
In September 2025, the FDA granted accelerated approval to Forzinity, the prescription

27
00:02:01,542 --> 00:02:07,083
elamipretide product, to improve muscle strength in adults and children with Barth syndrome

28
00:02:07,083 --> 00:02:10,708
weighing at least thirty kilograms.

29
00:02:10,708 --> 00:02:15,417
This approval is specific to the product, condition, and eligible population.

30
00:02:15,417 --> 00:02:20,542
The approval relied on improved knee-extensor strength as an intermediate clinical endpoint.

31
00:02:20,542 --> 00:02:26,083
A confirmatory trial is required to establish that this translates into patient benefit.

32
00:02:26,083 --> 00:02:31,208
It does not establish an anti-aging treatment or a general performance enhancer.

33
00:02:31,208 --> 00:02:35,917
Injection-site reactions are common, and serious allergic reactions have been reported.

34
00:02:35,917 --> 00:02:41,458
A research-use label on a vial does not make it the FDA-approved product.

35
00:02:41,458 --> 00:02:46,167
This overview is education, not a recommendation to use a compound.

36
00:02:46,167 --> 00:02:52,583
The key takeaway: identify the model, examine the endpoint, and keep the claim within the

37
00:02:52,583 --> 00:02:56,208
evidence.

38
00:02:56,208 --> 00:03:00,917
This original AXON educational draft uses on-screen captions and conceptual diagrams.

39
00:03:00,917 --> 00:03:04,542
Scientific and legal review are pending.

40
00:03:04,542 --> 00:03:08,167
The transcript and linked sources accompany the video.

41
00:03:08,167 --> 00:03:18,167
Read the original sources. Full citations and transcript accompany this film.